University of British Columbia and Precision NanoSystems Publish Lipid Nanoparticle Article in Langmuir

Press Release

January 23, 2012

Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, collaborated with scientists from the University of British Columbia to develop lipid nanoparticle systems using the NanoAssemblr technology. This work has been recently published in the journal, Langmuir (2012, 28 (7): 3633-3640). The article “Bottom-Up Design and Synthesis of Limit Size Lipid Nanoparticle Systems with Aqueous and Triglyceride Cores Using Millisecond Microfluidic Mixing” describes the development of “limit-size” systems (the smallest achieveable aggregates compatible with the packing of the molecular constiuents in a defined and energetically stable structure) with either polar, or non-polar cores. Liposome systems (polar core) comprising POPC, or POPC and cholesterol could be manufactured at limit sizes of 20 nm and 40 nm, respectively. Further, these systems were amenable to pH gradient-mediated  encapsulation of the anti-cancer drug, doxorubicin. Non-polar systems (nanoemulsions) formulated with the triglyceride triolein and the phospholipid POPC could be readily manipulated to vary particle size in the range 20 nm – 50 nm. To our knowledge this is the first report of stable triglyceride emulsions in this size range generated by a scalable manufacturing process.

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.


IN THE NEWS

Press Release

CanSinoBIO will license in Precision NanoSystems' proprietary RNA vaccine platform technology. Precision NanoSystems will lead RNA vaccine formulation development. CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials

Read More



Press Release

Precision NanoSystems is helping scientists to push the boundaries of neuroscience research with a range of efficient and easy-to-use primary cell transfection kits. Combining user-friendly NanoAssemblr™ microfluidics systems with advanced na...

Read More